New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2012
09:03 EDTASTMAastrom board names Dan Orlando interim CEO
Aastrom Biosciences announced that the company's board has named Dan Orlando interim CEO of Aastrom. Orlando, who joined Aastrom as Chief Commercial Officer in August, will assume the position of interim CEO effective December 14, 2012. Aastrom's president and CEO Tim Mayleben is retiring but will remain an active member of the company's board. Mayleben will continue to support the transition to a permanent CEO at the company for which a search is ongoing.
News For ASTM From The Last 14 Days
Check below for free stories on ASTM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2014
12:00 EDTASTMAastrom rises 32.7%
Subscribe for More Information
10:00 EDTASTMAastrom rises 26.1%
Aastrom is up 26.1%, or 92c, to $4.44
08:36 EDTASTMAastrom announces definitive agreement to acquire Sanofi's CTRM business
Aastrom Biosciences (ASTM) announced that it has entered into a definitive agreement to acquire Sanofi's (SNY) Cell Therapy and Regenerative Medicine, or CTRM, business for a purchase price of $6.5M, with $4M payable in cash at closing and $2.5M payable in the form of a promissory note. The acquisition is subject to customary closing conditions and is scheduled to close in approximately three weeks. Through the CTRM acquisition, Aastrom is acquiring global commercial rights to three marketed autologous cell therapy products. Aastrom will also acquire global manufacturing and production centers located in the United States and Denmark.
08:32 EDTASTMAastrom announces definitive agreement to acquire Sanofi's CTRM business
08:25 EDTASTMAastrom trading halted, pending news

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use